Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025

Sep 22, 2015, 09:00 ET from Visiongain

LONDON, September 22, 2015 /PRNewswire/ --

Nanopharma - Discover Revenue Prospects Now, Benefiting Your Authority
Do you want to find sales potentials of nanomedicine? If so, our new analysis gives you revenue forecasts to 2025 at overall world market, application, product and national level. That way you discover financial data, trends, R&D, opportunities and commercial outlooks.

Visiongain's study gives you revenue predictions from 2015 for nano-enabled drugs. There you explore trends, technologies and expected products, benefiting your reputation for technological and commercial insight. Discover what the future holds, staying ahead.

Our work explains the potential of nanomedicine to change pharma. See how those developments affect patients, healthcare providers and pharmaceutical companies.

Please read on to explore what drives and shapes that industry, also seeing revenue prediction.

Forecasts and other analysis show you where the best sales opportunities exist
Our new report shows revenue forecasting to 2025, recent results, growth rates and market shares. You explore quantitative and qualitative analyses, business news, research and development. You gain 34 tables, 44 charts and three interviews with other experts.

With that study you assess clinical, technological and commercial trends, results and potentials:
• Why will the nanopharma market expand fast - and what future revenues are possible?
• When will that worldwide industry achieve overall sales in hundreds of billion dollars?
• What products give the most promise for developers, producers and sellers?
• Who are the best-placed companies in that healthcare industry from 2015?
• Where are the most lucrative regions for selling those medicines?
• How will nanotechnological advances affect drug developers, marketers and manufacturers?

Many opportunities exist in healthcare for applications of nanotechnology. With our study you discover what segments are most likely to prosper. See potential sales from 2015.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Why struggle to find data, losing time and missing out? Instead help your research, analyses, plans, proposals and presentations. With our research and analysis, see how to save time and benefit your authority on nanomedicine.

That way you explore what the future holds for nanopharma. The following sections outline how our new investigation helps your work.

Predictions for that world market and submarkets - what sales growth is possible?
Along with revenue prediction for the overall world market for nanopharmaceuticals, our investigation shows you forecasts to 2025 for six individual therapeutic submarkets:
• Cancer
• Cardiovascular disorders
• Central nervous system (CNS) conditions
• Infectious diseases
• Inflammation
• Other applications of nanotechnology in pharmacotherapy.

Our report analyses sales potentials of those technological advances, showing how companies gain. That work can also benefit your authority on nanomedical applications, expanding your reputation for commercial and technological knowledge.

The new investigation discusses what stimulates and restrains sales of those treatments. You explore that industry, also seeing what products can achieve the most success.

Forecasting of leading products' sales - what revenues are possible for nanodrugs?
How will individual medicines perform from 2015 to 2025 at world level? Our study forecasts revenues of 13 brands:
• Abraxane
• Alimta
• Eligard
• Copaxone
• Rapamune
• Neulasta
• Cimzia.

Our sales predictions also cover these products:
• AmBisome
• MIRCERA
• Pegasys
• Emend
• Renagel
• Ritalin.

That work shows how high sales can go, revealing drugs and years with highest predicted revenues. You also examine competition. That way you investigate what is happening, understanding challenges, trends, R&D, competitors and opportunities.

Discover what the future holds. Our study also divides its overall world forecast into geographical segments.

Regional markets for nanomedicine - where will highest sales and growth occur?
Developments worldwide will influence the nano-enabled drugs market, raising demand for those therapies in developed and developing countries. Discover what success is possible.

Our analyses show you individual revenue forecasts to 2025 for five regional markets:
United States
Japan
• European Union
Asia Pacific
• Rest of world.

There you discover progress and outlooks. You assess the nanomedical industry's future - needs, developments, demands and their meaning. Our work explains, exploring issues affecting nanotechnological companies, influencing their work, results and potentials.

Forces affecting the nanopharma business - what shapes its present and future?
Our new report discusses pressures, opportunities and other events affecting the nanopharmaceutical industry and market from 2015, including these influences:
• Prominent nanomedicine companies by region - leading players
• Systems used in nanotechnology-enabled drug delivery
• Applications in therapeutics, implants, diagnostics and theranostics
• Nanoparticles - liposomes, polymers, quantum dots, superparamagnetic iron oxide (SPIO), carbon nanotubes and nanoshells
• Nanoparticle function, targeting, surface conjugation, improved bioavailability, tunability and controlled release systems
• Investments, infrastructure, networks and collaborations, as well as outlooks for regulatory guidelines and harmonisation.

Our survey also discusses research and development in nanomedicine, in particular for these product candidates:
• DermaVir (Genetic Immunity)
• CRLX101 (Cerulean Pharma)
• CPX-351 (Celator Pharma)
• NC-6004 (NanoCarrier)
• NK-105 (Nippon Kayaku)
• NK-012 (Nippon Kayaku)
• SGT-53 (SynerGene Therapeutics)
• BIND-014 (BIND Biosciences)

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

• ThermoDox (Celsion)
• ADI-PEG 20 (Polaris).

You assess the nanomedicine industry's strengths, weaknesses, opportunities and threats. That way you explore what restricts and stimulates companies, seeing what is possible.

Avoid falling behind. With our investigation you discover what the future holds for nano-enabled drugs, seeing prospects for their designers, producers and sellers.

Leading companies and overall 2017 revenue prediction
From 2015, product launches using nanotechnology hold great potential for investments, demand and sales. Our study predicts the world market for nanopharmaceuticals will reach $130bn in 2017, with strong revenue expansion from 2015 to 2025. Explore the potentials.

Our work assesses nanopharma technologies, products and companies holding the best prospects. You see what is possible for technological advances and revenue expansion.

Those analyses cover these companies and other developers, producers, marketers and technology suppliers:
• Sanofi
• BIND Therapeutics
• Merck
• Pfizer
• Cerulean Pharma
• Selecta Biosciences.

And you assess these nanopharma specialists, among others:
• Nanobiotix
• Magforce
• Celgene
• Celsion Corporation
• Nanocarrier.

You also examine three interviews with authorities in these organisations:
• Swiss Federal Laboratories for Materials Science and Technology
• Rexahn Pharmaceuticals
• Cristal Therapeutics.

From 2015 there will arise many opportunities. Our work shows you commercial possibilities for those novel drug technologies, helping you stay ahead in knowledge and succeed.

Ways Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025 helps
In the following main ways, our investigation helps your research, analyses, decisions, proposals and presentations:
• Revenues for nanopharma to 2025 at overall world level and for 6 submarkets and 13 products - find outlooks for R&D, production and sales
• Forecasts to 2025 for 5 regional markets - assess leading countries and regions for potential revenues, seeing what progress is possible
• Prospects for established competitors and rising companies - explore portfolios, results, strategies, technologies and outlooks for success
• Analysis of what encourages and restrains the nanomedicine industry - investigate challenges, strengths and competition affecting revenues and profits
• Interviews with authorities - discover what other experts think, say and do, helping you stay ahead in technological, medical and commercial insight.

That study - by visiongain's in-house analysts in the UK - gives knowledge to help your work, to spare you hassle and save time. You gain data leading companies depend on.

Information found nowhere else, benefiting your authority on pharma nanotechnology
Our survey gives independent analysis. There you gain competitive intelligence found only in our report, seeing where commercial prospects are most rewarding.

With our data you are less likely to fall behind in information or miss opportunity. Discover there how to benefit your searches, analyses, plans and decisions, also saving time and helping your influence.

So explore the future of nanomedicine. In our investigation you find data, trends, opportunities and multilevel sales predictions. Stay ahead by requesting our new report here now.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44-(0)-20-7336-6100

Or click on https://www.visiongain.com/Report/1500/Nanopharmaceutical-Industry-and-Market-Companies-Products-R-D-and-Revenue-Forecasts-2015-2025

Organisations Mentioned in the Report 

3M
Abbott
Abraxis
Access
Accord Healthcare
Ademtech
Agave Biosystems
Alcon
Allergan
Alrise Biosystems
AMAG Pharmaceuticals
Amgen
ANABior
Antnano
Apotex
AquaNova
Arrowhead Research
Astellas
AstraZeneca
Avidimer
Axialys Innovations
Azaya Therapeutics
Baxalta
Bayer
BBInternational
BIND Biosciences
BIND Therapeutics
Bioalliance
BioCellChallenge
Biomerieux
BIOMET
BioNanomatrix
Calando Pharmaceuticals
Capsulution
CarlinaTechnologies
Celator
Celator Pharma
Celgene
Cell Constraint Cancer
Celsion Corporation
Cerulean Pharma
Cezanne
ChemBiotech
Chemicell
ChipShop
Cisbio
Colcom Nanotech
Committee for Medicinal Products for Human Use (CHMP)
Cytimmune
Cytoo
Cytoplex Biosciences
DCN Corp
Eli Lilly
EMA
Empa
EndoMagnetics
Enzon Pharmaceuticals
Epeius
Etex
Ethypharm
EU-Nano Characterization Lab (EUNCL)
FDA
Flamel Technologies
Fleet Bioprocessing
Fluigent
Fresenius
Galen
Genetic Immunity
Genzyme
Gilead
GSK
Guerbet
iCEUTICA
Immunigon
IMSTAR
Inanovate
Innova Biosciences
InoDiag
Intas
Invitrogen
Janssen
Keystone Nano
Kylin Therapeutics
Lighthouse Biosciences
Liquidia
LTT Bio-Pharma
Magforce
MagnaMedics
Mantis Deposition
MAST Carbon International
medsqual
Merck & Co.
Midatech
Momento
Mylan
NanoBio
Nanobiotix
Nanocarrier
Nanoco Technologies
NanoCor Therapeutics
NanoDel
Nanoforce
NanoMedSyn
Nanomerics
Nanopore
Nanoprobes
Nanosight
Nanospectra Biosciences
NatCo
National Characterization Laboratory (NCL)
National Nanotechnology Initiatives (NNI)
NIH
Nippon Kayaku Co.
Novagali Pharma
Novartis
Novavax
Novosom AG
NSD
Otsuka
Oxonica
OZ Biosciences
PDS Biotechnology
PF Prism
Pfizer
PharmaSol
Phusis
Polaris
PolyMicrospheres
ProNAi
PST
Pylote
Qiagen
QuantuMD
RegenTec
Responsif
Rexahn Pharmaceuticals
Roche
Sandoz
Sanofi
Selecta Biosciences
Siemens
Sigma-Tau
Silence Therapeutics
Silicon Kinetics
SkyePharma
Smith&Nephew
Smiths Medical
Spirogen
SRU Biosystems
SynerGene Therapeutics
Synthon
T2 Biosystems
Taiho
Teva Pharmaceuticals
UCB
XstalBio
Zell Kontakt

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com


SOURCE Visiongain